Stifel raised the firm’s price target on Spyre Therapeutics to $27 from $23 and keeps a Buy rating on the shares as part of the 2024 Biotech Outlook Report. Spyre has a meaningful Phase 1 readout to support their half-life extension theses, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYRE:
- Spyre Therapeutics initiated with bullish view at Jefferies, here’s why
- Nike upgraded, Paramount downgraded: Wall Street’s top analyst calls
- Guggenheim starts Spyre Therapeutics with a Buy on ‘best-in-class’ IBD potential
- Spyre Therapeutics initiated with bullish view at Guggenheim
- Spyre Therapeutics initiated with bullish view at Jefferies
